By Fineline Cube 
Sino-US biotech Phanes Therapeutics Inc. announced that the first patient has been dosed in a clinical study evaluating peluntamig (PT217) in combination with chemotherapy. The trial focuses on patients with small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).
Drug Profile
Peluntamig is a bispecific antibody (BsAb) targeting DLL3 and CD47. The drug has been granted orphan drug designations (ODDs) by the US Food and Drug Administration (FDA) for SCLC and NEC.
Clinical Development
In addition to the current trial, peluntamig is being assessed in combination with Roche’s anti-PD-L1 therapy atezolizumab, following a clinical supply agreement with the Swiss firm last year. The drug is under investigation in multiple clinical studies to explore its potential in treating SCLC and NEC.-Fineline Info & Tech